Lead Product(s): Terbinafine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Nice & Green S.A
Deal Size: $21.2 million Upfront Cash: Undisclosed
Deal Type: Financing March 23, 2020
The agreement with N&G enables Moberg Pharma to pursue this potential and conduct an additional clinical study, depending on the outcome of the EU study expected at the end of Q2 2020.